GEMP Insider Trading Activity and SEC Form 4 Filings
GEMP insider trading summary
No open-market insider purchases or sales of Gemphire Therapeutics Inc. (GEMP) have been reported on SEC Form 4 in the past 12 months.
Latest GEMP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 8, 2018 | Steven R. Ph.D. Gullans | Interim President & CEO | Buy | $500K (71,429 @ $7.00) |
| Feb 8, 2018 | Seth Reno | Chief Commercial Officer | Buy | $100K (14,286 @ $7.00) |
| Mar 10, 2017 | Andy Sassine | Director | Buy | $200K (21,119 @ $9.47) |
| Mar 10, 2017 | Steven R. Ph.D. Gullans | Director | Buy | $500K (52,798 @ $9.47) |
| Mar 10, 2017 | P. Kent Hawryluk | Director | Buy | $237K (25,000 @ $9.47) |
| Mar 10, 2017 | Pedro Lichtinger | Director | Buy | $100K (10,559 @ $9.47) |
| Aug 10, 2016 | P. Kent Hawryluk | Director | Buy | $250K (25,000 @ $10.00) |
| Aug 10, 2016 | Seth Reno | Chief Commercial Officer | Buy | $40K (4,000 @ $10.00) |
| Aug 10, 2016 | Kenneth W Kousky | Director | Buy | $10K (1,000 @ $10.00) |
| Aug 10, 2016 | Mina Sooch | President & CEO | Buy | $525K (52,500 @ $10.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.